Melanoma

Oral capecitabine shows considerable early promise for the secondary prevention of nonmelanoma skin cancers in solid organ transplant recipients and other immunosuppressed individuals, according to Dr. Paul Nghiem.

Oral capecitabine shows considerable early promise for the secondary prevention of nonmelanoma skin cancers in solid organ transplant recipients and other immunosuppressed individuals, according to Dr. Paul Nghiem.

Oral capecitabine shows considerable early promise for the secondary prevention of nonmelanoma skin cancers in solid organ transplant recipients and other immunosuppressed individuals, according to Dr. Paul Nghiem.

The limitations of the drug approval process in fully characterizing a new drug's safety profile are clearly illustrated in the dermatologic therapeutics arena and clinicians should keep these limitations in mind when prescribing and counseling patients about a relatively new therapeutic agent, according to Dr. Joel M. Gelfand.

Previously unknown risks of new drugs are routinely identified after Food and Drug Administration approval, when "rare" adverse events are more likely to be detected, said Dr. Gelfand at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF). Examples of rare adverse events – those that occur at a rate of less than 1 per 1,000 – include fatal arrhythmias associated with terfenadine and astemizole, lymphomas associated with biologics, and progressive multifocal leukoencephalopathy (PML) associated with efalizumab.

The clinical trials that are the basis of drug approvals evaluate short-term safety only and lack the statistical power to detect rare events, he said, pointing out that a study of 3,000 patients can only detect adverse events that occur at a rate of more than 1 per 1,000.

The types of adverse effects detected pre-approval are pharmacologic side effects, which are common and dose dependent, such as isotretinoin-induced cheilitis, said Dr. Gelfand, of the department of dermatology at the University of Pennsylvania in Philadelphia.

Adverse effects that are detected after approval fall into two categories: idiosyncratic or allergic reactions, which are rare and "occur in close proximity to exposure," he said, such as dapsone-induced agranulocytosis, and new morbidities, which are delayed and uncommon. An example of the latter is skin cancers associated with psoralen and ultraviolet A (PUVA) treatment, which was associated with melanoma in 1997, more than 2 decades after it was found to be effective for treating psoriasis.

There is a need for ongoing risk assessment throughout the life cycle of a drug, Dr. Gelfand said, which includes MedWatch, the FDA's voluntary adverse event reporting program that relies on spontaneous reporting of adverse events. MedWatch's advantages include that it is inexpensive and can identify safety signals; however, it is limited by under-reporting and MedWatch reports usually cannot be used to determine causality, he noted.

The association between efalizumab (Raptiva) and PML, an untreatable and often fatal central nervous system infection that occurs primarily in the setting of immunosuppression, is an example of "signal detection in action," Dr. Gelfand said. Efalizumab was approved in 2003 for psoriasis, based on studies of about 2,700 people, including 218 treated for more than 1 year. By 2008, after 46,000 people had been treated, including 3,000 for at least 2 years, there had been 3 confirmed cases and one suspected case of PML. All four were spontaneous reports, which "can be useful for very rare diseases such as PML," he said.

With efalizumab treatment, the overall estimated risk of PML is 1 in 15,000 patients per year and one in 1,000 patients treated for more than 2 years. These are likely underestimates because of incomplete reporting, and is a relationship that is "likely causal," he said. In the case of efalizumab, the risk was "judged unacceptable given treatment alternatives and disease indication" and the drug was withdrawn from the market in 2009.

A causal association between isotretinoin and inflammatory bowel disease (IBD) has not been established, but the drug's prescribing information includes a warning about the association.

The data on isotretinoin and IBD include a large administrative claims database of over 8,000 cases of IBD, and 21,832 controls published in 2010 (Am. J. Gastroenterol. 2010;105:1986-93). Analysis of the database found that the risk of IBD within 12 months of being treated with isotretinoin was 1.7; for ulcerative colitis, the risk was increased fourfold; for Crohn's disease the risk was slightly reduced.

In that study, which controlled for age, sex, and geographic region, the dose response was evident for ulcerative colitis only, Dr. Gelfand said.

In a review of 85 spontaneous reports of IBD in isotretinoin patients to the FDA between 1997-2002, isotretinoin was considered "highly probable" as the cause in 4 cases (5%), "probable" in 58 cases (68%), and "possible" in 23 cases (27%). These included three cases with a positive dechallenge and rechallenge.

When in comes to ulcerative colitis, the overall data available "suggest a specific association" between isotretinoin and the disease, but the data are conflicting, he said. Studies have not addressed the possibility that patients with severe acne are at an increased risk of ulcerative colitis, or of confounding variables including oral antibiotics and smoking, he said. If the risk is real, it is small, with a number needed to harm that exceeds 3,300.

With these examples in mind, Dr. Gelfand advised clinicians to "use the science of medicine in judging safety... [and] the art of medicine" when communicating the risk of therapies to their patients.

"The benefits of treatments are well-characterized relative to the long-term safety and the risk of rare but serious medical events," he said. "Sir William Osler was the first to recognize the need to be cautious when prescribing new medications advising physicians 'Do not be the first to prescribe a new drug and do not be the last to stop prescribing an old drug.' "

Dr. Gelfand disclosed that he has been an investigator and/or consultant to Amgen, Abbott, Centocor, Pfizer, Celegene, Novartis, and Genentech, and that his presentation was his work only.

SDEF and this news organization are owned by Elsevier.

The limitations of the drug approval process in fully characterizing a new drug's safety profile are clearly illustrated in the dermatologic therapeutics arena and clinicians should keep these limitations in mind when prescribing and counseling patients about a relatively new therapeutic agent, according to Dr. Joel M. Gelfand.

Previously unknown risks of new drugs are routinely identified after Food and Drug Administration approval, when "rare" adverse events are more likely to be detected, said Dr. Gelfand at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF). Examples of rare adverse events – those that occur at a rate of less than 1 per 1,000 – include fatal arrhythmias associated with terfenadine and astemizole, lymphomas associated with biologics, and progressive multifocal leukoencephalopathy (PML) associated with efalizumab.

The clinical trials that are the basis of drug approvals evaluate short-term safety only and lack the statistical power to detect rare events, he said, pointing out that a study of 3,000 patients can only detect adverse events that occur at a rate of more than 1 per 1,000.

The types of adverse effects detected pre-approval are pharmacologic side effects, which are common and dose dependent, such as isotretinoin-induced cheilitis, said Dr. Gelfand, of the department of dermatology at the University of Pennsylvania in Philadelphia.

Adverse effects that are detected after approval fall into two categories: idiosyncratic or allergic reactions, which are rare and "occur in close proximity to exposure," he said, such as dapsone-induced agranulocytosis, and new morbidities, which are delayed and uncommon. An example of the latter is skin cancers associated with psoralen and ultraviolet A (PUVA) treatment, which was associated with melanoma in 1997, more than 2 decades after it was found to be effective for treating psoriasis.

There is a need for ongoing risk assessment throughout the life cycle of a drug, Dr. Gelfand said, which includes MedWatch, the FDA's voluntary adverse event reporting program that relies on spontaneous reporting of adverse events. MedWatch's advantages include that it is inexpensive and can identify safety signals; however, it is limited by under-reporting and MedWatch reports usually cannot be used to determine causality, he noted.

The association between efalizumab (Raptiva) and PML, an untreatable and often fatal central nervous system infection that occurs primarily in the setting of immunosuppression, is an example of "signal detection in action," Dr. Gelfand said. Efalizumab was approved in 2003 for psoriasis, based on studies of about 2,700 people, including 218 treated for more than 1 year. By 2008, after 46,000 people had been treated, including 3,000 for at least 2 years, there had been 3 confirmed cases and one suspected case of PML. All four were spontaneous reports, which "can be useful for very rare diseases such as PML," he said.

With efalizumab treatment, the overall estimated risk of PML is 1 in 15,000 patients per year and one in 1,000 patients treated for more than 2 years. These are likely underestimates because of incomplete reporting, and is a relationship that is "likely causal," he said. In the case of efalizumab, the risk was "judged unacceptable given treatment alternatives and disease indication" and the drug was withdrawn from the market in 2009.

A causal association between isotretinoin and inflammatory bowel disease (IBD) has not been established, but the drug's prescribing information includes a warning about the association.

The data on isotretinoin and IBD include a large administrative claims database of over 8,000 cases of IBD, and 21,832 controls published in 2010 (Am. J. Gastroenterol. 2010;105:1986-93). Analysis of the database found that the risk of IBD within 12 months of being treated with isotretinoin was 1.7; for ulcerative colitis, the risk was increased fourfold; for Crohn's disease the risk was slightly reduced.

In that study, which controlled for age, sex, and geographic region, the dose response was evident for ulcerative colitis only, Dr. Gelfand said.

In a review of 85 spontaneous reports of IBD in isotretinoin patients to the FDA between 1997-2002, isotretinoin was considered "highly probable" as the cause in 4 cases (5%), "probable" in 58 cases (68%), and "possible" in 23 cases (27%). These included three cases with a positive dechallenge and rechallenge.

When in comes to ulcerative colitis, the overall data available "suggest a specific association" between isotretinoin and the disease, but the data are conflicting, he said. Studies have not addressed the possibility that patients with severe acne are at an increased risk of ulcerative colitis, or of confounding variables including oral antibiotics and smoking, he said. If the risk is real, it is small, with a number needed to harm that exceeds 3,300.

With these examples in mind, Dr. Gelfand advised clinicians to "use the science of medicine in judging safety... [and] the art of medicine" when communicating the risk of therapies to their patients.

"The benefits of treatments are well-characterized relative to the long-term safety and the risk of rare but serious medical events," he said. "Sir William Osler was the first to recognize the need to be cautious when prescribing new medications advising physicians 'Do not be the first to prescribe a new drug and do not be the last to stop prescribing an old drug.' "

Dr. Gelfand disclosed that he has been an investigator and/or consultant to Amgen, Abbott, Centocor, Pfizer, Celegene, Novartis, and Genentech, and that his presentation was his work only.

SDEF and this news organization are owned by Elsevier.

The limitations of the drug approval process in fully characterizing a new drug's safety profile are clearly illustrated in the dermatologic therapeutics arena and clinicians should keep these limitations in mind when prescribing and counseling patients about a relatively new therapeutic agent, according to Dr. Joel M. Gelfand.

Previously unknown risks of new drugs are routinely identified after Food and Drug Administration approval, when "rare" adverse events are more likely to be detected, said Dr. Gelfand at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF). Examples of rare adverse events – those that occur at a rate of less than 1 per 1,000 – include fatal arrhythmias associated with terfenadine and astemizole, lymphomas associated with biologics, and progressive multifocal leukoencephalopathy (PML) associated with efalizumab.

The clinical trials that are the basis of drug approvals evaluate short-term safety only and lack the statistical power to detect rare events, he said, pointing out that a study of 3,000 patients can only detect adverse events that occur at a rate of more than 1 per 1,000.

The types of adverse effects detected pre-approval are pharmacologic side effects, which are common and dose dependent, such as isotretinoin-induced cheilitis, said Dr. Gelfand, of the department of dermatology at the University of Pennsylvania in Philadelphia.

Adverse effects that are detected after approval fall into two categories: idiosyncratic or allergic reactions, which are rare and "occur in close proximity to exposure," he said, such as dapsone-induced agranulocytosis, and new morbidities, which are delayed and uncommon. An example of the latter is skin cancers associated with psoralen and ultraviolet A (PUVA) treatment, which was associated with melanoma in 1997, more than 2 decades after it was found to be effective for treating psoriasis.

There is a need for ongoing risk assessment throughout the life cycle of a drug, Dr. Gelfand said, which includes MedWatch, the FDA's voluntary adverse event reporting program that relies on spontaneous reporting of adverse events. MedWatch's advantages include that it is inexpensive and can identify safety signals; however, it is limited by under-reporting and MedWatch reports usually cannot be used to determine causality, he noted.

The association between efalizumab (Raptiva) and PML, an untreatable and often fatal central nervous system infection that occurs primarily in the setting of immunosuppression, is an example of "signal detection in action," Dr. Gelfand said. Efalizumab was approved in 2003 for psoriasis, based on studies of about 2,700 people, including 218 treated for more than 1 year. By 2008, after 46,000 people had been treated, including 3,000 for at least 2 years, there had been 3 confirmed cases and one suspected case of PML. All four were spontaneous reports, which "can be useful for very rare diseases such as PML," he said.

With efalizumab treatment, the overall estimated risk of PML is 1 in 15,000 patients per year and one in 1,000 patients treated for more than 2 years. These are likely underestimates because of incomplete reporting, and is a relationship that is "likely causal," he said. In the case of efalizumab, the risk was "judged unacceptable given treatment alternatives and disease indication" and the drug was withdrawn from the market in 2009.

A causal association between isotretinoin and inflammatory bowel disease (IBD) has not been established, but the drug's prescribing information includes a warning about the association.

The data on isotretinoin and IBD include a large administrative claims database of over 8,000 cases of IBD, and 21,832 controls published in 2010 (Am. J. Gastroenterol. 2010;105:1986-93). Analysis of the database found that the risk of IBD within 12 months of being treated with isotretinoin was 1.7; for ulcerative colitis, the risk was increased fourfold; for Crohn's disease the risk was slightly reduced.

In that study, which controlled for age, sex, and geographic region, the dose response was evident for ulcerative colitis only, Dr. Gelfand said.

In a review of 85 spontaneous reports of IBD in isotretinoin patients to the FDA between 1997-2002, isotretinoin was considered "highly probable" as the cause in 4 cases (5%), "probable" in 58 cases (68%), and "possible" in 23 cases (27%). These included three cases with a positive dechallenge and rechallenge.

When in comes to ulcerative colitis, the overall data available "suggest a specific association" between isotretinoin and the disease, but the data are conflicting, he said. Studies have not addressed the possibility that patients with severe acne are at an increased risk of ulcerative colitis, or of confounding variables including oral antibiotics and smoking, he said. If the risk is real, it is small, with a number needed to harm that exceeds 3,300.

With these examples in mind, Dr. Gelfand advised clinicians to "use the science of medicine in judging safety... [and] the art of medicine" when communicating the risk of therapies to their patients.

"The benefits of treatments are well-characterized relative to the long-term safety and the risk of rare but serious medical events," he said. "Sir William Osler was the first to recognize the need to be cautious when prescribing new medications advising physicians 'Do not be the first to prescribe a new drug and do not be the last to stop prescribing an old drug.' "

Dr. Gelfand disclosed that he has been an investigator and/or consultant to Amgen, Abbott, Centocor, Pfizer, Celegene, Novartis, and Genentech, and that his presentation was his work only.

SDEF and this news organization are owned by Elsevier.

Theories of how nevi develop have received little attention in the last 100 years, but that appears to be changing, according to Dr. Ashfaq A. Marghoob.

Dr. Marghoob, a dermatologist at Memorial Sloan-Kettering Cancer Center in New York, discussed what is currently known about nevogenesis. "Since nevi are associated with an increased risk of melanoma, understanding nevogenesis may help to unravel some of the mysteries of melanomagenesis," he noted at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF).

German physician Paul Gerson Unna proposed the "Abtropfung" theory of nevogenesis in 1893. The theory holds that melanocytic nevus cells develop in the epidermis and drop off to the dermis over time. "For almost a century this theory of nevogenesis was accepted as truth and remained uncontested," Dr. Marghoob said.

During the past few decades, however, newly acquired observations from histopathology and embryogenesis have led some researchers to question the validity of the "Abtropfung" theory in favor of the "Hochsteigerung" theory.

Dr. Stewart F. Cramer, a pathologist, proposed the latter in 1984. It essentially is the reverse of the Abtropfung theory, meaning that nevus cells migrate from the dermis to the epidermis.

Photo courtesy Dr. Ashfaq A. Marghoob

For example, in one histopathology study, no child younger than 10 had a purely junctional nevus, 52% had compound nevi, and 48% had dermal nevi (Am. J. Dermatopathol. 1998;20:135-9). In patients older than age 60, 12% had junctional nevi, 23% had compound nevi, and 65% had dermal nevi. Had the Abtropfung theory been correct, most childhood nevi would be junctional, and most nevi in late adult life would be intradermal. The researchers said their findings better fit the theory of upward migration of nevus cells.

In another study, researchers reviewed all biopsy reports for junctional nevi from 2001 at the Penn State Milton S. Hershey Medical Center and found that these lesions occur with similar frequency in the young and in the elderly (J. Am. Acad. Dermatol 2007;56:825-7).

Photo courtesy Dr. Ashfaq A. Marghoob

"However, new insights gained from the epidemiology of nevi, cross-sectional and longitudinal study of nevi, dermoscopy and confocal microscopy investigation of nevi, as well as the cellular and molecular study of nevi, brings into question the aforementioned theories," Dr. Marghoob says.

In fact, he added, there is insufficient evidence that either theory is the norm in postnatal life. More longitudinal studies are needed to determine nevus evolution.

Dr. Marghoob reported having no relevant conflicts of interest. SDEF and this news organization are owned by Elsevier.

Theories of how nevi develop have received little attention in the last 100 years, but that appears to be changing, according to Dr. Ashfaq A. Marghoob.

Dr. Marghoob, a dermatologist at Memorial Sloan-Kettering Cancer Center in New York, discussed what is currently known about nevogenesis. "Since nevi are associated with an increased risk of melanoma, understanding nevogenesis may help to unravel some of the mysteries of melanomagenesis," he noted at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF).

German physician Paul Gerson Unna proposed the "Abtropfung" theory of nevogenesis in 1893. The theory holds that melanocytic nevus cells develop in the epidermis and drop off to the dermis over time. "For almost a century this theory of nevogenesis was accepted as truth and remained uncontested," Dr. Marghoob said.

During the past few decades, however, newly acquired observations from histopathology and embryogenesis have led some researchers to question the validity of the "Abtropfung" theory in favor of the "Hochsteigerung" theory.

Dr. Stewart F. Cramer, a pathologist, proposed the latter in 1984. It essentially is the reverse of the Abtropfung theory, meaning that nevus cells migrate from the dermis to the epidermis.

Photo courtesy Dr. Ashfaq A. Marghoob

For example, in one histopathology study, no child younger than 10 had a purely junctional nevus, 52% had compound nevi, and 48% had dermal nevi (Am. J. Dermatopathol. 1998;20:135-9). In patients older than age 60, 12% had junctional nevi, 23% had compound nevi, and 65% had dermal nevi. Had the Abtropfung theory been correct, most childhood nevi would be junctional, and most nevi in late adult life would be intradermal. The researchers said their findings better fit the theory of upward migration of nevus cells.

In another study, researchers reviewed all biopsy reports for junctional nevi from 2001 at the Penn State Milton S. Hershey Medical Center and found that these lesions occur with similar frequency in the young and in the elderly (J. Am. Acad. Dermatol 2007;56:825-7).

Photo courtesy Dr. Ashfaq A. Marghoob

"However, new insights gained from the epidemiology of nevi, cross-sectional and longitudinal study of nevi, dermoscopy and confocal microscopy investigation of nevi, as well as the cellular and molecular study of nevi, brings into question the aforementioned theories," Dr. Marghoob says.

In fact, he added, there is insufficient evidence that either theory is the norm in postnatal life. More longitudinal studies are needed to determine nevus evolution.

Dr. Marghoob reported having no relevant conflicts of interest. SDEF and this news organization are owned by Elsevier.

Theories of how nevi develop have received little attention in the last 100 years, but that appears to be changing, according to Dr. Ashfaq A. Marghoob.

Dr. Marghoob, a dermatologist at Memorial Sloan-Kettering Cancer Center in New York, discussed what is currently known about nevogenesis. "Since nevi are associated with an increased risk of melanoma, understanding nevogenesis may help to unravel some of the mysteries of melanomagenesis," he noted at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF).

German physician Paul Gerson Unna proposed the "Abtropfung" theory of nevogenesis in 1893. The theory holds that melanocytic nevus cells develop in the epidermis and drop off to the dermis over time. "For almost a century this theory of nevogenesis was accepted as truth and remained uncontested," Dr. Marghoob said.

During the past few decades, however, newly acquired observations from histopathology and embryogenesis have led some researchers to question the validity of the "Abtropfung" theory in favor of the "Hochsteigerung" theory.

Dr. Stewart F. Cramer, a pathologist, proposed the latter in 1984. It essentially is the reverse of the Abtropfung theory, meaning that nevus cells migrate from the dermis to the epidermis.

Photo courtesy Dr. Ashfaq A. Marghoob

For example, in one histopathology study, no child younger than 10 had a purely junctional nevus, 52% had compound nevi, and 48% had dermal nevi (Am. J. Dermatopathol. 1998;20:135-9). In patients older than age 60, 12% had junctional nevi, 23% had compound nevi, and 65% had dermal nevi. Had the Abtropfung theory been correct, most childhood nevi would be junctional, and most nevi in late adult life would be intradermal. The researchers said their findings better fit the theory of upward migration of nevus cells.

In another study, researchers reviewed all biopsy reports for junctional nevi from 2001 at the Penn State Milton S. Hershey Medical Center and found that these lesions occur with similar frequency in the young and in the elderly (J. Am. Acad. Dermatol 2007;56:825-7).

Photo courtesy Dr. Ashfaq A. Marghoob

"However, new insights gained from the epidemiology of nevi, cross-sectional and longitudinal study of nevi, dermoscopy and confocal microscopy investigation of nevi, as well as the cellular and molecular study of nevi, brings into question the aforementioned theories," Dr. Marghoob says.

In fact, he added, there is insufficient evidence that either theory is the norm in postnatal life. More longitudinal studies are needed to determine nevus evolution.

Dr. Marghoob reported having no relevant conflicts of interest. SDEF and this news organization are owned by Elsevier.

During the past 30 years, only two drugs – dacarbazine and interleukin-2 – have been approved by the Food and Drug Administration for treating metastatic melanoma, and while these drugs help control the disease in a small percentage of patients, they do not appear to improve survival.

However, agents introduced within the last 2 years are reported to improve survival, Dr. Richard D. Carvajal of Memorial Sloan-Kettering Cancer Center, said at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF).

The first is ipilimumab (also known as MDX-010 or MDX-101), a monoclonal antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Normally, CTLA-4 slows the immune system, but this treatment allows the immune system to recognize melanoma, Dr. Carvajal said.

In one study reported last year, ipilimumab improved overall survival in patients with previously treated metastatic melanoma (N. Engl. J. Med. 2010;363;711-23). Specifically, patients who received ipilimumab plus glycoprotein 100 (gp100) had an overall survival of 10 months, while those who received gp100 alone had a survival rate of 6.4 months. The median overall survival for patients taking ipilimumab alone was 10.1 months.

The second treatment, PLX4032 (also known as RG7204 or RO5185426), works by inhibiting the mutated BRAF protein found in about half of all cases of metastatic melanoma. In January, the manufacturer, Plexxikon, announced that a phase III clinical study showed a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma.

Study participants who received PLX4032 lived longer (overall survival) and also lived longer without their disease getting worse (progression-free survival), compared with participants who received dacarbazine, the current standard of care, Dr. Carvajal said, adding "these are really large breakthroughs."

Dr. Carvajal disclosed that he has served as a consultant for Novartis. SDEF and this news organization are owned by Elsevier.

During the past 30 years, only two drugs – dacarbazine and interleukin-2 – have been approved by the Food and Drug Administration for treating metastatic melanoma, and while these drugs help control the disease in a small percentage of patients, they do not appear to improve survival.

However, agents introduced within the last 2 years are reported to improve survival, Dr. Richard D. Carvajal of Memorial Sloan-Kettering Cancer Center, said at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF).

The first is ipilimumab (also known as MDX-010 or MDX-101), a monoclonal antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Normally, CTLA-4 slows the immune system, but this treatment allows the immune system to recognize melanoma, Dr. Carvajal said.

In one study reported last year, ipilimumab improved overall survival in patients with previously treated metastatic melanoma (N. Engl. J. Med. 2010;363;711-23). Specifically, patients who received ipilimumab plus glycoprotein 100 (gp100) had an overall survival of 10 months, while those who received gp100 alone had a survival rate of 6.4 months. The median overall survival for patients taking ipilimumab alone was 10.1 months.

The second treatment, PLX4032 (also known as RG7204 or RO5185426), works by inhibiting the mutated BRAF protein found in about half of all cases of metastatic melanoma. In January, the manufacturer, Plexxikon, announced that a phase III clinical study showed a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma.

Study participants who received PLX4032 lived longer (overall survival) and also lived longer without their disease getting worse (progression-free survival), compared with participants who received dacarbazine, the current standard of care, Dr. Carvajal said, adding "these are really large breakthroughs."

Dr. Carvajal disclosed that he has served as a consultant for Novartis. SDEF and this news organization are owned by Elsevier.

During the past 30 years, only two drugs – dacarbazine and interleukin-2 – have been approved by the Food and Drug Administration for treating metastatic melanoma, and while these drugs help control the disease in a small percentage of patients, they do not appear to improve survival.

However, agents introduced within the last 2 years are reported to improve survival, Dr. Richard D. Carvajal of Memorial Sloan-Kettering Cancer Center, said at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF).

The first is ipilimumab (also known as MDX-010 or MDX-101), a monoclonal antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Normally, CTLA-4 slows the immune system, but this treatment allows the immune system to recognize melanoma, Dr. Carvajal said.

In one study reported last year, ipilimumab improved overall survival in patients with previously treated metastatic melanoma (N. Engl. J. Med. 2010;363;711-23). Specifically, patients who received ipilimumab plus glycoprotein 100 (gp100) had an overall survival of 10 months, while those who received gp100 alone had a survival rate of 6.4 months. The median overall survival for patients taking ipilimumab alone was 10.1 months.

The second treatment, PLX4032 (also known as RG7204 or RO5185426), works by inhibiting the mutated BRAF protein found in about half of all cases of metastatic melanoma. In January, the manufacturer, Plexxikon, announced that a phase III clinical study showed a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma.

Study participants who received PLX4032 lived longer (overall survival) and also lived longer without their disease getting worse (progression-free survival), compared with participants who received dacarbazine, the current standard of care, Dr. Carvajal said, adding "these are really large breakthroughs."

Dr. Carvajal disclosed that he has served as a consultant for Novartis. SDEF and this news organization are owned by Elsevier.

During the past 30 years, only two drugs – dacarbazine and interleukin-2 – have been approved by the Food and Drug Administration for treating metastatic melanoma, and while these drugs help control the disease in a small percentage of patients, they do not appear to improve survival.

However, agents introduced within the last 2 years are reported to improve survival, Dr. Richard D. Carvajal of Memorial Sloan-Kettering Cancer Center, said at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF).

The first is ipilimumab (also known as MDX-010), a monoclonal antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA4). Normally, CTLA4 functions as one of several negative feedback mechanisms within the immune system. Treatment with ipilimumab takes away this negative feedback mechanism and allows the immune system to recognize and combat melanoma, Dr. Carvajal said.

In one study reported last year, ipilimumab improved overall survival in patients with previously treated metastatic melanoma (N. Engl. J. Med. 2010;363;711-23). Specifically, patients who received ipilimumab plus glycoprotein 100 (gp100) vaccine had an overall survival of 10 months, while those who received gp100 alone had a survival rate of 6.4 months. The median overall survival for patients taking ipilimumab alone was 10.1 months.

Even more striking, the 1-year overall survival rate for patients receiving ipilimumab alone or in combination with the vaccine was approximately 45%, significantly better than the 1-year overall survival rate of 25% achieved with the vaccine alone.

The second agent, PLX4032 (also known as RG7204 or RO5185426), works by inhibiting the mutated BRAF protein found in about half of all cases of metastatic melanoma. In January, the manufacturer, Plexxikon, announced that a phase III clinical study showed a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma.

Study participants who received PLX4032 lived longer (overall survival) and also lived longer without their disease getting worse (progression-free survival), compared with participants who received dacarbazine, the current standard of care.

"As these are the first two drugs ever demonstrated to improve survival in patients with advanced melanoma, these recent developments are extremely significant breakthroughs for the management of this disease," Dr. Carvajal said.

Dr. Carvajal disclosed that he has served as a consultant for Novartis. SDEF and this news organization are owned by Elsevier.

During the past 30 years, only two drugs – dacarbazine and interleukin-2 – have been approved by the Food and Drug Administration for treating metastatic melanoma, and while these drugs help control the disease in a small percentage of patients, they do not appear to improve survival.

However, agents introduced within the last 2 years are reported to improve survival, Dr. Richard D. Carvajal of Memorial Sloan-Kettering Cancer Center, said at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF).

The first is ipilimumab (also known as MDX-010), a monoclonal antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA4). Normally, CTLA4 functions as one of several negative feedback mechanisms within the immune system. Treatment with ipilimumab takes away this negative feedback mechanism and allows the immune system to recognize and combat melanoma, Dr. Carvajal said.

In one study reported last year, ipilimumab improved overall survival in patients with previously treated metastatic melanoma (N. Engl. J. Med. 2010;363;711-23). Specifically, patients who received ipilimumab plus glycoprotein 100 (gp100) vaccine had an overall survival of 10 months, while those who received gp100 alone had a survival rate of 6.4 months. The median overall survival for patients taking ipilimumab alone was 10.1 months.

Even more striking, the 1-year overall survival rate for patients receiving ipilimumab alone or in combination with the vaccine was approximately 45%, significantly better than the 1-year overall survival rate of 25% achieved with the vaccine alone.

The second agent, PLX4032 (also known as RG7204 or RO5185426), works by inhibiting the mutated BRAF protein found in about half of all cases of metastatic melanoma. In January, the manufacturer, Plexxikon, announced that a phase III clinical study showed a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma.

Study participants who received PLX4032 lived longer (overall survival) and also lived longer without their disease getting worse (progression-free survival), compared with participants who received dacarbazine, the current standard of care.

"As these are the first two drugs ever demonstrated to improve survival in patients with advanced melanoma, these recent developments are extremely significant breakthroughs for the management of this disease," Dr. Carvajal said.

Dr. Carvajal disclosed that he has served as a consultant for Novartis. SDEF and this news organization are owned by Elsevier.

During the past 30 years, only two drugs – dacarbazine and interleukin-2 – have been approved by the Food and Drug Administration for treating metastatic melanoma, and while these drugs help control the disease in a small percentage of patients, they do not appear to improve survival.

However, agents introduced within the last 2 years are reported to improve survival, Dr. Richard D. Carvajal of Memorial Sloan-Kettering Cancer Center, said at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF).

The first is ipilimumab (also known as MDX-010), a monoclonal antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA4). Normally, CTLA4 functions as one of several negative feedback mechanisms within the immune system. Treatment with ipilimumab takes away this negative feedback mechanism and allows the immune system to recognize and combat melanoma, Dr. Carvajal said.

In one study reported last year, ipilimumab improved overall survival in patients with previously treated metastatic melanoma (N. Engl. J. Med. 2010;363;711-23). Specifically, patients who received ipilimumab plus glycoprotein 100 (gp100) vaccine had an overall survival of 10 months, while those who received gp100 alone had a survival rate of 6.4 months. The median overall survival for patients taking ipilimumab alone was 10.1 months.

Even more striking, the 1-year overall survival rate for patients receiving ipilimumab alone or in combination with the vaccine was approximately 45%, significantly better than the 1-year overall survival rate of 25% achieved with the vaccine alone.

The second agent, PLX4032 (also known as RG7204 or RO5185426), works by inhibiting the mutated BRAF protein found in about half of all cases of metastatic melanoma. In January, the manufacturer, Plexxikon, announced that a phase III clinical study showed a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma.

Study participants who received PLX4032 lived longer (overall survival) and also lived longer without their disease getting worse (progression-free survival), compared with participants who received dacarbazine, the current standard of care.

"As these are the first two drugs ever demonstrated to improve survival in patients with advanced melanoma, these recent developments are extremely significant breakthroughs for the management of this disease," Dr. Carvajal said.

Dr. Carvajal disclosed that he has served as a consultant for Novartis. SDEF and this news organization are owned by Elsevier.

Clinical observation calls into question some of the preconceived notions about melanoma pathogenesis, according to Dr. James M. Grichnik.

The traditional model is that melanomas initially develop from differentiated melanocytes in the epidermis and then invade the dermis. This is largely based on pathologic features, said Dr. Grichnik, director of the melanoma program at Sylvester Cancer Comprehensive Center, and professor of dermatology at the University of Miami. Specifically, the lowest-risk melanoma in situ tumors are thought to remain in the epidermis, while higher-risk tumors invade the deeper dermal tissues.

However, there is a newer model of melanomagenesis that is based on stem cell biology, Dr. Grichnik said at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF). The model suggests that stem cells in the dermis can become mature epidermal melanocytes, and that early epigenetic or genetic alterations leading to transformation may take place in the dermis rather than in the epidermis (J. Invest. Dermatol. 2008;128:2365-80).

Also, stem cell markers CD166, CD133, and nestin are expressed at significantly higher levels in melanoma compared to banal nevi. Nestin was found to be significantly increased in metastatic melanoma, compared with primary melanoma, suggesting this subpopulation of cells may be particularly virulent (Mod. Pathol. 2007;20:102-7).

The problem with tumor stem cell components, however, is that they may not have normal antigens, and components may escape into the lymph system rather than adhere to the lymph nodes.

"So, the immune system doesn't do a good job of catching them," Dr. Grichnik said, adding that tumors contain a heterogeneous population of cells. "They're trying to differentiate towards a normal pigment of cells, the melanocytes. Some of the heterogeneous population has the antigens that the immune system destroys, but the stem cell population doesn't."

Recognition of these pathways may lead to better diagnostic and therapeutic tools. A multiple treatment approach most likely will be needed.

"One approach is to destroy proliferative cells and another is to destroy the nonproliferative tumor stem cells," Dr. Grichnik said. "We'll have to develop therapies that are specific to the tumor stem cells."

Dr. Grichnik disclosed that he is a major shareholder and founder of DigitalDerm, and serves in a consultant role for Electro-Optical Systems and Spectral Image.

SDEF and this news organization are owned by Elsevier.

Clinical observation calls into question some of the preconceived notions about melanoma pathogenesis, according to Dr. James M. Grichnik.

The traditional model is that melanomas initially develop from differentiated melanocytes in the epidermis and then invade the dermis. This is largely based on pathologic features, said Dr. Grichnik, director of the melanoma program at Sylvester Cancer Comprehensive Center, and professor of dermatology at the University of Miami. Specifically, the lowest-risk melanoma in situ tumors are thought to remain in the epidermis, while higher-risk tumors invade the deeper dermal tissues.

However, there is a newer model of melanomagenesis that is based on stem cell biology, Dr. Grichnik said at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF). The model suggests that stem cells in the dermis can become mature epidermal melanocytes, and that early epigenetic or genetic alterations leading to transformation may take place in the dermis rather than in the epidermis (J. Invest. Dermatol. 2008;128:2365-80).

Also, stem cell markers CD166, CD133, and nestin are expressed at significantly higher levels in melanoma compared to banal nevi. Nestin was found to be significantly increased in metastatic melanoma, compared with primary melanoma, suggesting this subpopulation of cells may be particularly virulent (Mod. Pathol. 2007;20:102-7).

The problem with tumor stem cell components, however, is that they may not have normal antigens, and components may escape into the lymph system rather than adhere to the lymph nodes.

"So, the immune system doesn't do a good job of catching them," Dr. Grichnik said, adding that tumors contain a heterogeneous population of cells. "They're trying to differentiate towards a normal pigment of cells, the melanocytes. Some of the heterogeneous population has the antigens that the immune system destroys, but the stem cell population doesn't."

Recognition of these pathways may lead to better diagnostic and therapeutic tools. A multiple treatment approach most likely will be needed.

"One approach is to destroy proliferative cells and another is to destroy the nonproliferative tumor stem cells," Dr. Grichnik said. "We'll have to develop therapies that are specific to the tumor stem cells."

Dr. Grichnik disclosed that he is a major shareholder and founder of DigitalDerm, and serves in a consultant role for Electro-Optical Systems and Spectral Image.

SDEF and this news organization are owned by Elsevier.

Clinical observation calls into question some of the preconceived notions about melanoma pathogenesis, according to Dr. James M. Grichnik.

The traditional model is that melanomas initially develop from differentiated melanocytes in the epidermis and then invade the dermis. This is largely based on pathologic features, said Dr. Grichnik, director of the melanoma program at Sylvester Cancer Comprehensive Center, and professor of dermatology at the University of Miami. Specifically, the lowest-risk melanoma in situ tumors are thought to remain in the epidermis, while higher-risk tumors invade the deeper dermal tissues.

However, there is a newer model of melanomagenesis that is based on stem cell biology, Dr. Grichnik said at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF). The model suggests that stem cells in the dermis can become mature epidermal melanocytes, and that early epigenetic or genetic alterations leading to transformation may take place in the dermis rather than in the epidermis (J. Invest. Dermatol. 2008;128:2365-80).

Also, stem cell markers CD166, CD133, and nestin are expressed at significantly higher levels in melanoma compared to banal nevi. Nestin was found to be significantly increased in metastatic melanoma, compared with primary melanoma, suggesting this subpopulation of cells may be particularly virulent (Mod. Pathol. 2007;20:102-7).

The problem with tumor stem cell components, however, is that they may not have normal antigens, and components may escape into the lymph system rather than adhere to the lymph nodes.

"So, the immune system doesn't do a good job of catching them," Dr. Grichnik said, adding that tumors contain a heterogeneous population of cells. "They're trying to differentiate towards a normal pigment of cells, the melanocytes. Some of the heterogeneous population has the antigens that the immune system destroys, but the stem cell population doesn't."

Recognition of these pathways may lead to better diagnostic and therapeutic tools. A multiple treatment approach most likely will be needed.

"One approach is to destroy proliferative cells and another is to destroy the nonproliferative tumor stem cells," Dr. Grichnik said. "We'll have to develop therapies that are specific to the tumor stem cells."

Dr. Grichnik disclosed that he is a major shareholder and founder of DigitalDerm, and serves in a consultant role for Electro-Optical Systems and Spectral Image.

SDEF and this news organization are owned by Elsevier.

SAN ANTONIO – The development of a serum glycoprotein microarray has led to the discovery of four proteins for which antibodies significantly predict nodal metastases in patients with melanoma.

If validated, the data could form the basis of a blood test to select patients for sentinel lymph node biopsy, Dr. Michael Sabel said during a symposium sponsored by the Society of Surgical Oncology.

In an internal validation cohort of 79 patients with newly diagnosed melanoma, 22 patients (28%) had serum antibodies to acid ceramidase (ASAH1), cathepsin D (CTSD), or lactate dehydrogenase B (LDHB) that were significantly associated with being node negative (P value less than .0001; hazard ratio, 0.173).

"This isn't a small percentage of patients, so if validated, this test could significantly reduce the number of patients to whom we offer sentinel node biopsy," he said in an interview.

Antibodies to a fourth protein, GRP94 (also known as heat shock protein 90), were detected in nine patients (11%), and were significantly associated with being node positive (P less than .0001; HR, 3.04).

"Theoretically, this could be used in patients who are on the borderline for the procedure, where the presence of antibodies to GRP94 could prompt you to use sentinel node biopsy," Dr. Sabel said.

Surprisingly, the presence of antibodies to GRP94 did not correlate with the volume of disease burden within the sentinel node. The antibodies were equally present in patients who had microscopic disease and in those with more significant tumor burden within their sentinel node.

The bigger picture, however, is the potential for glycoprotein microarray analysis to identify predictive and prognostic biomarkers in melanoma, suggested Dr. Sabel, a surgical oncologist with the University of Michigan Health Systems in Ann Arbor.

Studies are ongoing to find other antibodies and their relevant glycoproteins that may differentiate benign from malignant skin lesions, identify patients at high risk of distant metastases, and signal response to adjuvant therapies.

"Glycoproteins have apparently important roles in melanoma progression, and also may serve as targets for therapy," he said.

The use of serum autoantibody profiling would be particularly attractive in clinical practice because it does not require primary tumor tissue. Unlike most other solid tumors, roughly 90% of a primary melanoma tumor is removed during the initial biopsy, leaving little tissue for subsequent testing once the diagnosis has been made, Dr. Sabel said.

Sentinel node biopsy with selective lymph node dissection was endorsed in the latest American Joint Commission on Cancer staging guidelines for melanoma, but it is positive in only 20% of patients with melanoma, he observed.

The researchers studied glycoproteins rather than a broad array of proteins because glycoproteins have a strong interaction with the immune system. This is particularly advantageous in melanoma because the interaction between the immune system and melanoma is well documented. In addition, glycoproteins undergo distinct changes during cancer progression, including precancerous states and posttranslational modifications that are associated with disease progression, Dr. Sabel explained.

In order to perform serum autoantibody profiling, the researchers used dual-lectin affinity and reverse-phase chromatography to separate out glycoproteins from a whole cell lysate created from a metastatic melanoma cell line. The glycoproteins were spotted on a microarray and tested using serum from 43 melanoma patients, with anti–human IgG used to detect response, Dr. Sabel said.

Wilcoxon rank-sum testing and outlier analysis identified nine fractions that significantly separated 27 node-negative patients from 16 node-positive patients. Mass spectrometry was then used to identify the relevant proteins of interest. Prevalidation testing with recombinant proteins boiled down the nine fractions to the four proteins used in the validation set of 79 patients.

Interestingly, although LDHB, CTSD, and GRP94 have strong associations with melanoma, the ASAH1 protein has been associated with breast, thyroid, and prostate cancers, but not melanoma, Dr. Sabel said.

In multivariate analysis of the validation cohort, there was no significant correlation among the four proteins or between the proteins and known melanoma prognostic factors. Only a mild, negative correlation was observed between ASAHI and increasing age, he said.

All four antibodies remained significant after adjustment for age, sex, Breslow thickness, ulceration, and mitotic rate, with a receiver operating characteristic area under the curve of 0.8690.

Dr. Sabel disclosed research funding from Merck Oncology. His coauthors report no conflicts.

SAN ANTONIO – The development of a serum glycoprotein microarray has led to the discovery of four proteins for which antibodies significantly predict nodal metastases in patients with melanoma.

If validated, the data could form the basis of a blood test to select patients for sentinel lymph node biopsy, Dr. Michael Sabel said during a symposium sponsored by the Society of Surgical Oncology.

In an internal validation cohort of 79 patients with newly diagnosed melanoma, 22 patients (28%) had serum antibodies to acid ceramidase (ASAH1), cathepsin D (CTSD), or lactate dehydrogenase B (LDHB) that were significantly associated with being node negative (P value less than .0001; hazard ratio, 0.173).

"This isn't a small percentage of patients, so if validated, this test could significantly reduce the number of patients to whom we offer sentinel node biopsy," he said in an interview.

Antibodies to a fourth protein, GRP94 (also known as heat shock protein 90), were detected in nine patients (11%), and were significantly associated with being node positive (P less than .0001; HR, 3.04).

"Theoretically, this could be used in patients who are on the borderline for the procedure, where the presence of antibodies to GRP94 could prompt you to use sentinel node biopsy," Dr. Sabel said.

Surprisingly, the presence of antibodies to GRP94 did not correlate with the volume of disease burden within the sentinel node. The antibodies were equally present in patients who had microscopic disease and in those with more significant tumor burden within their sentinel node.

The bigger picture, however, is the potential for glycoprotein microarray analysis to identify predictive and prognostic biomarkers in melanoma, suggested Dr. Sabel, a surgical oncologist with the University of Michigan Health Systems in Ann Arbor.

Studies are ongoing to find other antibodies and their relevant glycoproteins that may differentiate benign from malignant skin lesions, identify patients at high risk of distant metastases, and signal response to adjuvant therapies.

"Glycoproteins have apparently important roles in melanoma progression, and also may serve as targets for therapy," he said.

The use of serum autoantibody profiling would be particularly attractive in clinical practice because it does not require primary tumor tissue. Unlike most other solid tumors, roughly 90% of a primary melanoma tumor is removed during the initial biopsy, leaving little tissue for subsequent testing once the diagnosis has been made, Dr. Sabel said.

Sentinel node biopsy with selective lymph node dissection was endorsed in the latest American Joint Commission on Cancer staging guidelines for melanoma, but it is positive in only 20% of patients with melanoma, he observed.

The researchers studied glycoproteins rather than a broad array of proteins because glycoproteins have a strong interaction with the immune system. This is particularly advantageous in melanoma because the interaction between the immune system and melanoma is well documented. In addition, glycoproteins undergo distinct changes during cancer progression, including precancerous states and posttranslational modifications that are associated with disease progression, Dr. Sabel explained.

In order to perform serum autoantibody profiling, the researchers used dual-lectin affinity and reverse-phase chromatography to separate out glycoproteins from a whole cell lysate created from a metastatic melanoma cell line. The glycoproteins were spotted on a microarray and tested using serum from 43 melanoma patients, with anti–human IgG used to detect response, Dr. Sabel said.

Wilcoxon rank-sum testing and outlier analysis identified nine fractions that significantly separated 27 node-negative patients from 16 node-positive patients. Mass spectrometry was then used to identify the relevant proteins of interest. Prevalidation testing with recombinant proteins boiled down the nine fractions to the four proteins used in the validation set of 79 patients.

Interestingly, although LDHB, CTSD, and GRP94 have strong associations with melanoma, the ASAH1 protein has been associated with breast, thyroid, and prostate cancers, but not melanoma, Dr. Sabel said.

In multivariate analysis of the validation cohort, there was no significant correlation among the four proteins or between the proteins and known melanoma prognostic factors. Only a mild, negative correlation was observed between ASAHI and increasing age, he said.

All four antibodies remained significant after adjustment for age, sex, Breslow thickness, ulceration, and mitotic rate, with a receiver operating characteristic area under the curve of 0.8690.

Dr. Sabel disclosed research funding from Merck Oncology. His coauthors report no conflicts.

SAN ANTONIO – The development of a serum glycoprotein microarray has led to the discovery of four proteins for which antibodies significantly predict nodal metastases in patients with melanoma.

If validated, the data could form the basis of a blood test to select patients for sentinel lymph node biopsy, Dr. Michael Sabel said during a symposium sponsored by the Society of Surgical Oncology.

In an internal validation cohort of 79 patients with newly diagnosed melanoma, 22 patients (28%) had serum antibodies to acid ceramidase (ASAH1), cathepsin D (CTSD), or lactate dehydrogenase B (LDHB) that were significantly associated with being node negative (P value less than .0001; hazard ratio, 0.173).

"This isn't a small percentage of patients, so if validated, this test could significantly reduce the number of patients to whom we offer sentinel node biopsy," he said in an interview.

Antibodies to a fourth protein, GRP94 (also known as heat shock protein 90), were detected in nine patients (11%), and were significantly associated with being node positive (P less than .0001; HR, 3.04).

"Theoretically, this could be used in patients who are on the borderline for the procedure, where the presence of antibodies to GRP94 could prompt you to use sentinel node biopsy," Dr. Sabel said.

Surprisingly, the presence of antibodies to GRP94 did not correlate with the volume of disease burden within the sentinel node. The antibodies were equally present in patients who had microscopic disease and in those with more significant tumor burden within their sentinel node.

The bigger picture, however, is the potential for glycoprotein microarray analysis to identify predictive and prognostic biomarkers in melanoma, suggested Dr. Sabel, a surgical oncologist with the University of Michigan Health Systems in Ann Arbor.

Studies are ongoing to find other antibodies and their relevant glycoproteins that may differentiate benign from malignant skin lesions, identify patients at high risk of distant metastases, and signal response to adjuvant therapies.

"Glycoproteins have apparently important roles in melanoma progression, and also may serve as targets for therapy," he said.

The use of serum autoantibody profiling would be particularly attractive in clinical practice because it does not require primary tumor tissue. Unlike most other solid tumors, roughly 90% of a primary melanoma tumor is removed during the initial biopsy, leaving little tissue for subsequent testing once the diagnosis has been made, Dr. Sabel said.

Sentinel node biopsy with selective lymph node dissection was endorsed in the latest American Joint Commission on Cancer staging guidelines for melanoma, but it is positive in only 20% of patients with melanoma, he observed.

The researchers studied glycoproteins rather than a broad array of proteins because glycoproteins have a strong interaction with the immune system. This is particularly advantageous in melanoma because the interaction between the immune system and melanoma is well documented. In addition, glycoproteins undergo distinct changes during cancer progression, including precancerous states and posttranslational modifications that are associated with disease progression, Dr. Sabel explained.

In order to perform serum autoantibody profiling, the researchers used dual-lectin affinity and reverse-phase chromatography to separate out glycoproteins from a whole cell lysate created from a metastatic melanoma cell line. The glycoproteins were spotted on a microarray and tested using serum from 43 melanoma patients, with anti–human IgG used to detect response, Dr. Sabel said.

Wilcoxon rank-sum testing and outlier analysis identified nine fractions that significantly separated 27 node-negative patients from 16 node-positive patients. Mass spectrometry was then used to identify the relevant proteins of interest. Prevalidation testing with recombinant proteins boiled down the nine fractions to the four proteins used in the validation set of 79 patients.

Interestingly, although LDHB, CTSD, and GRP94 have strong associations with melanoma, the ASAH1 protein has been associated with breast, thyroid, and prostate cancers, but not melanoma, Dr. Sabel said.

In multivariate analysis of the validation cohort, there was no significant correlation among the four proteins or between the proteins and known melanoma prognostic factors. Only a mild, negative correlation was observed between ASAHI and increasing age, he said.

All four antibodies remained significant after adjustment for age, sex, Breslow thickness, ulceration, and mitotic rate, with a receiver operating characteristic area under the curve of 0.8690.

Dr. Sabel disclosed research funding from Merck Oncology. His coauthors report no conflicts.

NEW ORLEANS - When a patient presents with patches of lighter skin and you immediately go through the most likely clinical culprits in your head, don't forget to include hypochromia in your differential diagnosis among the common hypopigmentation disorders, Dr. James J. Nordlund said.

Although most diagnoses will not be definitive without a biopsy, your clinical suspicions are essential to alert your pathologist to look for subtle signs that in some cases can make a big difference in clinical treatment and outcomes, Dr. Nordlund said.

Mycosis fungoides, progressive macular hypomelanosis, sarcoidosis, and pityriasis alba are true hypopigmentation disorders characterized by decreases in melanin in the skin. In contrast, hypochromia or patches of light- or white-colored skin, can throw you off until the pathology report reveals normal melanin levels.

"These are some of the problems I struggle with. They are common and I see them every day, and I certainly have some successes and failures," Dr. Nordlund said at the annual meeting of the American Society of Dermatology.

A misdiagnosis of hypopigmentation "is probably the biggest problem when we don't get a great response in patients. You have to ask yourself if the condition is related to a melanin decrease," said Dr. Nordlund, professor of clinical dermatology at Wright State University in Dayton, Ohio.

Nevus anemicus is an example of hypochromia. This vascular anomaly often mimics hypopigmentation, Dr. Nordlund said. Scars also can cause hypochromia. A Wood's lamp might reveal excessive collagen in the dermis and decreased vascularity with scar tissue. "It appears to be depigmentation but it's not."

Mycosis fungoides, in contrast, is a true hypopigmentation disorder. The ultraviolet glow of a Wood's lamp, however, will be insufficient for most diagnoses. The clinical presentation is vague, so a biopsy helps to identify this condition, Dr. Nordlund said. He performs longitudinal shave biopsies if there is any doubt.

"It's important to keep hypopigmentation mycosis fungoides in mind as a cause of hypopigmentation on the trunk and extremities," Dr. Nordlund said. "Alert your pathologist to this possible diagnosis so they can look for the subtle signs."

Mycosis fungoides is more common in darker skin, affects both children and adults, and generally has a good prognosis. Treatment response generally is better with narrow-band ultraviolet B phototherapy or psoralen and ultraviolet A (PUVA) therapy than with topical steroids.

You also may see hypopigmentation in association with sarcoidosis, a granulomatous inflammation that most often presents as red, indurated nodules on the skin, although it can affect any or all organs. A punch biopsy can confirm if a lesion is sarcoid, Dr. Nordlund said. "You really cannot be sure except with histology."

A biopsy also helps to distinguish mycosis fungoides or sarcoidosis from a third hypopigmentation disorder called progressive macular hypomelanosis. Ill-defined macules typically begin on the back and spread, sparing the face, in darker-skinned patients. A meeting attendee asked if there are diagnostic studies for this condition. Dr. Nordlund said no. "I biopsy them, because I don't think it's distinguishable from mycosis fungoides or sarcoidosis. That is all I do, biopsy." Pathology generally reveals a mild-to-moderate deficiency of melanin.

This is "one disorder I see too often for my own desires. It's hard to treat," Dr. Nordlund said. PUVA is an option, but the hypopigmentation can return after treatment is discontinued. Some researchers suggest the condition is a form of Pityrosporum (now called Malassezia) infection, he added. "Minocycline 100 mg with benzoyl peroxide - I've tried this off-label approach - and sometimes I get a response."

There also is an idiopathic form. In idiopathic guttate hypomelanosis, melanocytes usually are present but melanization is suppressed. The epidermis will appear normal to slightly atrophic. Pathogenesis might be genetic and/or due to exposure to sunlight, "but I can't convince myself of the sunlight etiology," Dr. Nordlund said.

Also consider pityriasis alba, characterized by hypopigmentation with slight scaling but no pruritus, in your differential diagnosis. This condition is very common in children and young adults.

"From my own experience, UV light is not very helpful," Dr. Nordlund said.

"Oftentimes the mistake is to use high-potency steroids, which also suppress melanin. You essentially turn off melanin production and don't get a good response." Instead, he recommended long-term, mild steroid treatment with a product such as Desonide Lotion (available as a generic).

Tinea versicolor is a common infection that also causes hypopigmentation. The yeastlike Malassezia furfur fungus infects the stratum corneum. The condition is easily treated with topical or oral ketoconazole, Dr. Nordlund said, but complete response can take time. "Warn patients that hypopigmentation can persist for months."

Dr. Nordlund said that he had no relevant financial disclosures.

NEW ORLEANS - When a patient presents with patches of lighter skin and you immediately go through the most likely clinical culprits in your head, don't forget to include hypochromia in your differential diagnosis among the common hypopigmentation disorders, Dr. James J. Nordlund said.

Although most diagnoses will not be definitive without a biopsy, your clinical suspicions are essential to alert your pathologist to look for subtle signs that in some cases can make a big difference in clinical treatment and outcomes, Dr. Nordlund said.

Mycosis fungoides, progressive macular hypomelanosis, sarcoidosis, and pityriasis alba are true hypopigmentation disorders characterized by decreases in melanin in the skin. In contrast, hypochromia or patches of light- or white-colored skin, can throw you off until the pathology report reveals normal melanin levels.

"These are some of the problems I struggle with. They are common and I see them every day, and I certainly have some successes and failures," Dr. Nordlund said at the annual meeting of the American Society of Dermatology.

A misdiagnosis of hypopigmentation "is probably the biggest problem when we don't get a great response in patients. You have to ask yourself if the condition is related to a melanin decrease," said Dr. Nordlund, professor of clinical dermatology at Wright State University in Dayton, Ohio.

Nevus anemicus is an example of hypochromia. This vascular anomaly often mimics hypopigmentation, Dr. Nordlund said. Scars also can cause hypochromia. A Wood's lamp might reveal excessive collagen in the dermis and decreased vascularity with scar tissue. "It appears to be depigmentation but it's not."

Mycosis fungoides, in contrast, is a true hypopigmentation disorder. The ultraviolet glow of a Wood's lamp, however, will be insufficient for most diagnoses. The clinical presentation is vague, so a biopsy helps to identify this condition, Dr. Nordlund said. He performs longitudinal shave biopsies if there is any doubt.

"It's important to keep hypopigmentation mycosis fungoides in mind as a cause of hypopigmentation on the trunk and extremities," Dr. Nordlund said. "Alert your pathologist to this possible diagnosis so they can look for the subtle signs."

Mycosis fungoides is more common in darker skin, affects both children and adults, and generally has a good prognosis. Treatment response generally is better with narrow-band ultraviolet B phototherapy or psoralen and ultraviolet A (PUVA) therapy than with topical steroids.

You also may see hypopigmentation in association with sarcoidosis, a granulomatous inflammation that most often presents as red, indurated nodules on the skin, although it can affect any or all organs. A punch biopsy can confirm if a lesion is sarcoid, Dr. Nordlund said. "You really cannot be sure except with histology."

A biopsy also helps to distinguish mycosis fungoides or sarcoidosis from a third hypopigmentation disorder called progressive macular hypomelanosis. Ill-defined macules typically begin on the back and spread, sparing the face, in darker-skinned patients. A meeting attendee asked if there are diagnostic studies for this condition. Dr. Nordlund said no. "I biopsy them, because I don't think it's distinguishable from mycosis fungoides or sarcoidosis. That is all I do, biopsy." Pathology generally reveals a mild-to-moderate deficiency of melanin.

This is "one disorder I see too often for my own desires. It's hard to treat," Dr. Nordlund said. PUVA is an option, but the hypopigmentation can return after treatment is discontinued. Some researchers suggest the condition is a form of Pityrosporum (now called Malassezia) infection, he added. "Minocycline 100 mg with benzoyl peroxide - I've tried this off-label approach - and sometimes I get a response."

There also is an idiopathic form. In idiopathic guttate hypomelanosis, melanocytes usually are present but melanization is suppressed. The epidermis will appear normal to slightly atrophic. Pathogenesis might be genetic and/or due to exposure to sunlight, "but I can't convince myself of the sunlight etiology," Dr. Nordlund said.

Also consider pityriasis alba, characterized by hypopigmentation with slight scaling but no pruritus, in your differential diagnosis. This condition is very common in children and young adults.

"From my own experience, UV light is not very helpful," Dr. Nordlund said.

"Oftentimes the mistake is to use high-potency steroids, which also suppress melanin. You essentially turn off melanin production and don't get a good response." Instead, he recommended long-term, mild steroid treatment with a product such as Desonide Lotion (available as a generic).

Tinea versicolor is a common infection that also causes hypopigmentation. The yeastlike Malassezia furfur fungus infects the stratum corneum. The condition is easily treated with topical or oral ketoconazole, Dr. Nordlund said, but complete response can take time. "Warn patients that hypopigmentation can persist for months."

Dr. Nordlund said that he had no relevant financial disclosures.

NEW ORLEANS - When a patient presents with patches of lighter skin and you immediately go through the most likely clinical culprits in your head, don't forget to include hypochromia in your differential diagnosis among the common hypopigmentation disorders, Dr. James J. Nordlund said.

Although most diagnoses will not be definitive without a biopsy, your clinical suspicions are essential to alert your pathologist to look for subtle signs that in some cases can make a big difference in clinical treatment and outcomes, Dr. Nordlund said.

Mycosis fungoides, progressive macular hypomelanosis, sarcoidosis, and pityriasis alba are true hypopigmentation disorders characterized by decreases in melanin in the skin. In contrast, hypochromia or patches of light- or white-colored skin, can throw you off until the pathology report reveals normal melanin levels.

"These are some of the problems I struggle with. They are common and I see them every day, and I certainly have some successes and failures," Dr. Nordlund said at the annual meeting of the American Society of Dermatology.

A misdiagnosis of hypopigmentation "is probably the biggest problem when we don't get a great response in patients. You have to ask yourself if the condition is related to a melanin decrease," said Dr. Nordlund, professor of clinical dermatology at Wright State University in Dayton, Ohio.

Nevus anemicus is an example of hypochromia. This vascular anomaly often mimics hypopigmentation, Dr. Nordlund said. Scars also can cause hypochromia. A Wood's lamp might reveal excessive collagen in the dermis and decreased vascularity with scar tissue. "It appears to be depigmentation but it's not."

Mycosis fungoides, in contrast, is a true hypopigmentation disorder. The ultraviolet glow of a Wood's lamp, however, will be insufficient for most diagnoses. The clinical presentation is vague, so a biopsy helps to identify this condition, Dr. Nordlund said. He performs longitudinal shave biopsies if there is any doubt.

"It's important to keep hypopigmentation mycosis fungoides in mind as a cause of hypopigmentation on the trunk and extremities," Dr. Nordlund said. "Alert your pathologist to this possible diagnosis so they can look for the subtle signs."

Mycosis fungoides is more common in darker skin, affects both children and adults, and generally has a good prognosis. Treatment response generally is better with narrow-band ultraviolet B phototherapy or psoralen and ultraviolet A (PUVA) therapy than with topical steroids.

You also may see hypopigmentation in association with sarcoidosis, a granulomatous inflammation that most often presents as red, indurated nodules on the skin, although it can affect any or all organs. A punch biopsy can confirm if a lesion is sarcoid, Dr. Nordlund said. "You really cannot be sure except with histology."

A biopsy also helps to distinguish mycosis fungoides or sarcoidosis from a third hypopigmentation disorder called progressive macular hypomelanosis. Ill-defined macules typically begin on the back and spread, sparing the face, in darker-skinned patients. A meeting attendee asked if there are diagnostic studies for this condition. Dr. Nordlund said no. "I biopsy them, because I don't think it's distinguishable from mycosis fungoides or sarcoidosis. That is all I do, biopsy." Pathology generally reveals a mild-to-moderate deficiency of melanin.

This is "one disorder I see too often for my own desires. It's hard to treat," Dr. Nordlund said. PUVA is an option, but the hypopigmentation can return after treatment is discontinued. Some researchers suggest the condition is a form of Pityrosporum (now called Malassezia) infection, he added. "Minocycline 100 mg with benzoyl peroxide - I've tried this off-label approach - and sometimes I get a response."

There also is an idiopathic form. In idiopathic guttate hypomelanosis, melanocytes usually are present but melanization is suppressed. The epidermis will appear normal to slightly atrophic. Pathogenesis might be genetic and/or due to exposure to sunlight, "but I can't convince myself of the sunlight etiology," Dr. Nordlund said.

Also consider pityriasis alba, characterized by hypopigmentation with slight scaling but no pruritus, in your differential diagnosis. This condition is very common in children and young adults.

"From my own experience, UV light is not very helpful," Dr. Nordlund said.

"Oftentimes the mistake is to use high-potency steroids, which also suppress melanin. You essentially turn off melanin production and don't get a good response." Instead, he recommended long-term, mild steroid treatment with a product such as Desonide Lotion (available as a generic).

Tinea versicolor is a common infection that also causes hypopigmentation. The yeastlike Malassezia furfur fungus infects the stratum corneum. The condition is easily treated with topical or oral ketoconazole, Dr. Nordlund said, but complete response can take time. "Warn patients that hypopigmentation can persist for months."

Dr. Nordlund said that he had no relevant financial disclosures.

NEW ORLEANS – A higher baseline percentage of monocytes in patients with Sézary syndrome constitutes a previously unrecognized and potent predictor of clinical response to multimodality therapy incorporating extracorporeal photopheresis.

"Our theory as to why a higher number of monocytes is associated with better outcome is that it possibly leads to increased apoptosis of tumor cells and production of monocyte-derived cytokines, including interleukin-12 and interferon-alpha," Brian Raphael explained at the annual meeting of the American Academy of Dermatology.

Mr. Raphael, a fourth-year medical student at the University of Pennsylvania, Philadelphia, presented a retrospective cohort study analyzing response predictors in 97 patients with Sézary syndrome treated with multimodality therapy, defined as more than 2 months of extracorporeal photopheresis (ECP) plus at least one other systemic immunostimulatory therapy, such as interferon-alpha, interferon-gamma, sargramostim, or systemic retinoids.

This is believed to be the largest-ever such study looking at response markers, according to Mr. Raphael. Sézary syndrome is the leukemic form of cutaneous T-cell lymphoma. The prognosis is poor, with published average 5-year survival rates of only 30%.

ECP has long been considered first-line therapy for erythrodermic patients. At some centers it is employed as monotherapy, but at the University of Pennsylvania, it is typically utilized in a multimodal approach. The rationale is that combining ECP with various systemic immunostimulatory agents enhances antigen presentation, augments antitumor immunity, induces apoptosis through multiple mechanisms, and discourages tumor cell resistance, he said.

In this series, 49 of the 97 patients had stage IIIA or IIIB disease using the 1979 National Cancer Institute classification. The remainder had stage IVA or IVB Sézary syndrome.

One of the most impressive study findings, in the investigators' view, was the 30% complete response rate seen with multimodality therapy. Studies of ECP monotherapy typically cite complete response rates of about 20%, with a complete response being defined in the standard way as resolution of both skin and blood disease.

The partial response rate in the University of Pennsylvania series – defined as at least 50% improvement in both skin and blood disease – was 45%. This made for an overall 75% significant improvement rate with multimodality therapy, compared with a mean 63% significant improvement in previously reported studies of ECP monotherapy.

"These better outcomes suggest multimodality therapy is more effective than monotherapy," Mr. Raphael observed.

More than 50 patient and treatment variables were examined as potential predictors of outcome in the University of Pennsylvania series. The new one to emerge was monocyte percentage at initiation of therapy, which was a median of 9.5% in complete responders, significantly higher than the 7.8% in partial responders and 7.3% in nonresponders and those with progressive disease.

The other three significant predictors of a complete response had previously been identified in other studies. They included a lower ratio of CD4 to CD8 cells – 13.2 in complete responders, 48.7 in partial responders, and 44.2 in nonresponders – and fewer peripherally circulating abnormal T cells at baseline. The mean percentage of circulating CD26-negative lymphocytes was 27.4% in complete responders, 50.7% in partial responders, and 57.2% in nonresponders. Similarly, the mean percentage of circulating lymphocytes that were CD7 negative was 20.1% in complete responders, 36.4% in partial responders, and 41.3% in nonresponders.

Unlike in studies of ECP monotherapy for Sézary syndrome, age at diagnosis, white blood cell count, and disease stage were not significant predictors of a complete response to multimodality therapy in the new study.

Complete responders underwent a mean of 27 ECP sessions, compared with 35.5 in partial responders and 15 in nonresponders.

Mean baseline serum lactate dehydrogenase was 593 U/L in partial responders, compared with 707 U/L in nonresponders. This rather marked difference didn't achieve statistical significance, but that may change with greater patient numbers. In addition to expanding the study size, the investigators hope eventually to identify the most effective multimodality therapeutic combinations for particular patients.

Mr. Raphael said he had no relevant financial disclosures.

NEW ORLEANS – A higher baseline percentage of monocytes in patients with Sézary syndrome constitutes a previously unrecognized and potent predictor of clinical response to multimodality therapy incorporating extracorporeal photopheresis.

"Our theory as to why a higher number of monocytes is associated with better outcome is that it possibly leads to increased apoptosis of tumor cells and production of monocyte-derived cytokines, including interleukin-12 and interferon-alpha," Brian Raphael explained at the annual meeting of the American Academy of Dermatology.

Mr. Raphael, a fourth-year medical student at the University of Pennsylvania, Philadelphia, presented a retrospective cohort study analyzing response predictors in 97 patients with Sézary syndrome treated with multimodality therapy, defined as more than 2 months of extracorporeal photopheresis (ECP) plus at least one other systemic immunostimulatory therapy, such as interferon-alpha, interferon-gamma, sargramostim, or systemic retinoids.

This is believed to be the largest-ever such study looking at response markers, according to Mr. Raphael. Sézary syndrome is the leukemic form of cutaneous T-cell lymphoma. The prognosis is poor, with published average 5-year survival rates of only 30%.

ECP has long been considered first-line therapy for erythrodermic patients. At some centers it is employed as monotherapy, but at the University of Pennsylvania, it is typically utilized in a multimodal approach. The rationale is that combining ECP with various systemic immunostimulatory agents enhances antigen presentation, augments antitumor immunity, induces apoptosis through multiple mechanisms, and discourages tumor cell resistance, he said.

In this series, 49 of the 97 patients had stage IIIA or IIIB disease using the 1979 National Cancer Institute classification. The remainder had stage IVA or IVB Sézary syndrome.

One of the most impressive study findings, in the investigators' view, was the 30% complete response rate seen with multimodality therapy. Studies of ECP monotherapy typically cite complete response rates of about 20%, with a complete response being defined in the standard way as resolution of both skin and blood disease.

The partial response rate in the University of Pennsylvania series – defined as at least 50% improvement in both skin and blood disease – was 45%. This made for an overall 75% significant improvement rate with multimodality therapy, compared with a mean 63% significant improvement in previously reported studies of ECP monotherapy.

"These better outcomes suggest multimodality therapy is more effective than monotherapy," Mr. Raphael observed.

More than 50 patient and treatment variables were examined as potential predictors of outcome in the University of Pennsylvania series. The new one to emerge was monocyte percentage at initiation of therapy, which was a median of 9.5% in complete responders, significantly higher than the 7.8% in partial responders and 7.3% in nonresponders and those with progressive disease.

The other three significant predictors of a complete response had previously been identified in other studies. They included a lower ratio of CD4 to CD8 cells – 13.2 in complete responders, 48.7 in partial responders, and 44.2 in nonresponders – and fewer peripherally circulating abnormal T cells at baseline. The mean percentage of circulating CD26-negative lymphocytes was 27.4% in complete responders, 50.7% in partial responders, and 57.2% in nonresponders. Similarly, the mean percentage of circulating lymphocytes that were CD7 negative was 20.1% in complete responders, 36.4% in partial responders, and 41.3% in nonresponders.

Unlike in studies of ECP monotherapy for Sézary syndrome, age at diagnosis, white blood cell count, and disease stage were not significant predictors of a complete response to multimodality therapy in the new study.

Complete responders underwent a mean of 27 ECP sessions, compared with 35.5 in partial responders and 15 in nonresponders.

Mean baseline serum lactate dehydrogenase was 593 U/L in partial responders, compared with 707 U/L in nonresponders. This rather marked difference didn't achieve statistical significance, but that may change with greater patient numbers. In addition to expanding the study size, the investigators hope eventually to identify the most effective multimodality therapeutic combinations for particular patients.

Mr. Raphael said he had no relevant financial disclosures.

NEW ORLEANS – A higher baseline percentage of monocytes in patients with Sézary syndrome constitutes a previously unrecognized and potent predictor of clinical response to multimodality therapy incorporating extracorporeal photopheresis.

"Our theory as to why a higher number of monocytes is associated with better outcome is that it possibly leads to increased apoptosis of tumor cells and production of monocyte-derived cytokines, including interleukin-12 and interferon-alpha," Brian Raphael explained at the annual meeting of the American Academy of Dermatology.

Mr. Raphael, a fourth-year medical student at the University of Pennsylvania, Philadelphia, presented a retrospective cohort study analyzing response predictors in 97 patients with Sézary syndrome treated with multimodality therapy, defined as more than 2 months of extracorporeal photopheresis (ECP) plus at least one other systemic immunostimulatory therapy, such as interferon-alpha, interferon-gamma, sargramostim, or systemic retinoids.

This is believed to be the largest-ever such study looking at response markers, according to Mr. Raphael. Sézary syndrome is the leukemic form of cutaneous T-cell lymphoma. The prognosis is poor, with published average 5-year survival rates of only 30%.

ECP has long been considered first-line therapy for erythrodermic patients. At some centers it is employed as monotherapy, but at the University of Pennsylvania, it is typically utilized in a multimodal approach. The rationale is that combining ECP with various systemic immunostimulatory agents enhances antigen presentation, augments antitumor immunity, induces apoptosis through multiple mechanisms, and discourages tumor cell resistance, he said.

In this series, 49 of the 97 patients had stage IIIA or IIIB disease using the 1979 National Cancer Institute classification. The remainder had stage IVA or IVB Sézary syndrome.

One of the most impressive study findings, in the investigators' view, was the 30% complete response rate seen with multimodality therapy. Studies of ECP monotherapy typically cite complete response rates of about 20%, with a complete response being defined in the standard way as resolution of both skin and blood disease.

The partial response rate in the University of Pennsylvania series – defined as at least 50% improvement in both skin and blood disease – was 45%. This made for an overall 75% significant improvement rate with multimodality therapy, compared with a mean 63% significant improvement in previously reported studies of ECP monotherapy.

"These better outcomes suggest multimodality therapy is more effective than monotherapy," Mr. Raphael observed.

More than 50 patient and treatment variables were examined as potential predictors of outcome in the University of Pennsylvania series. The new one to emerge was monocyte percentage at initiation of therapy, which was a median of 9.5% in complete responders, significantly higher than the 7.8% in partial responders and 7.3% in nonresponders and those with progressive disease.

The other three significant predictors of a complete response had previously been identified in other studies. They included a lower ratio of CD4 to CD8 cells – 13.2 in complete responders, 48.7 in partial responders, and 44.2 in nonresponders – and fewer peripherally circulating abnormal T cells at baseline. The mean percentage of circulating CD26-negative lymphocytes was 27.4% in complete responders, 50.7% in partial responders, and 57.2% in nonresponders. Similarly, the mean percentage of circulating lymphocytes that were CD7 negative was 20.1% in complete responders, 36.4% in partial responders, and 41.3% in nonresponders.

Unlike in studies of ECP monotherapy for Sézary syndrome, age at diagnosis, white blood cell count, and disease stage were not significant predictors of a complete response to multimodality therapy in the new study.

Complete responders underwent a mean of 27 ECP sessions, compared with 35.5 in partial responders and 15 in nonresponders.

Mean baseline serum lactate dehydrogenase was 593 U/L in partial responders, compared with 707 U/L in nonresponders. This rather marked difference didn't achieve statistical significance, but that may change with greater patient numbers. In addition to expanding the study size, the investigators hope eventually to identify the most effective multimodality therapeutic combinations for particular patients.

Mr. Raphael said he had no relevant financial disclosures.

Matthew R. Donaldson, MD, and Brett M. Coldiron, MD

The incidence of nonmelanoma skin cancer (NMSC) continues to increase.  Multiple reports from the United States and Europe suggest we are in the midst of an epidemic. European studies show substantial NMSC incidence increases during the last 2 decades. In the United States, a recent analysis of Medicare Claims data showed that procedures performed for NMSC nearly doubled from 1994 to 2006. From these data, the total number of new NMSC in 2006 was estimated to be 3,507,693. Procedure data for 2006-2008 from the 5% Medicare Claims sample dataset corroborate the reported trajectory of incidence increase. Destructions, excisions, and Mohs procedures for NMSC have increased by 2.6% per year during the last 2 years. On the basis of this current rate of increase, the annual incidence of NMSC in the United States in 2008 would be nearly 3.69 million. Recognizing the NMSC epidemic is critical as the incidence—and cost—will continue to increase.

*For a PDF of the full article, click on the link to the left of this introduction.

Matthew R. Donaldson, MD, and Brett M. Coldiron, MD

The incidence of nonmelanoma skin cancer (NMSC) continues to increase.  Multiple reports from the United States and Europe suggest we are in the midst of an epidemic. European studies show substantial NMSC incidence increases during the last 2 decades. In the United States, a recent analysis of Medicare Claims data showed that procedures performed for NMSC nearly doubled from 1994 to 2006. From these data, the total number of new NMSC in 2006 was estimated to be 3,507,693. Procedure data for 2006-2008 from the 5% Medicare Claims sample dataset corroborate the reported trajectory of incidence increase. Destructions, excisions, and Mohs procedures for NMSC have increased by 2.6% per year during the last 2 years. On the basis of this current rate of increase, the annual incidence of NMSC in the United States in 2008 would be nearly 3.69 million. Recognizing the NMSC epidemic is critical as the incidence—and cost—will continue to increase.

*For a PDF of the full article, click on the link to the left of this introduction.

Matthew R. Donaldson, MD, and Brett M. Coldiron, MD

The incidence of nonmelanoma skin cancer (NMSC) continues to increase.  Multiple reports from the United States and Europe suggest we are in the midst of an epidemic. European studies show substantial NMSC incidence increases during the last 2 decades. In the United States, a recent analysis of Medicare Claims data showed that procedures performed for NMSC nearly doubled from 1994 to 2006. From these data, the total number of new NMSC in 2006 was estimated to be 3,507,693. Procedure data for 2006-2008 from the 5% Medicare Claims sample dataset corroborate the reported trajectory of incidence increase. Destructions, excisions, and Mohs procedures for NMSC have increased by 2.6% per year during the last 2 years. On the basis of this current rate of increase, the annual incidence of NMSC in the United States in 2008 would be nearly 3.69 million. Recognizing the NMSC epidemic is critical as the incidence—and cost—will continue to increase.

*For a PDF of the full article, click on the link to the left of this introduction.